Newsroom
The latest news for the myeloma community, covering such topics as: Co-pay assistance, changes in U.S. health care legislation, FDA drug approvals, research updates, and more.
www.myeloma.orgHere are the latest publicly reported developments in myeloma (as of 2025–2026), with a quick scan of credible sources.
What’s happening now
- Immunotherapies and CAR-T progress: Several CAR-T and bispecific antibody strategies remain at the forefront, with ongoing Phase 2/3 results and regulatory discussions shaping their use in relapsed/refractory myeloma. These include BCMA-targeted approaches and next-generation multispecific constructs that aim to broaden efficacy and manage safety.[1][4]
- Combination regimens and approvals: In several regions, combinations of monoclonal antibodies with standard backbones (e.g., daratumumab-containing regimens) continue to be evaluated for newly diagnosed and relapsed settings, with some combinations moving toward regulatory decisions or guideline updates.[4][8]
- Regulatory and guidance updates: Health authorities and professional societies periodically publish updated guidance on risk stratification, sequencing of therapies, and management of adverse events related to newer agents, including antibody-drug conjugates and CAR-T therapies.[1][4]
What this means for patients
- Access to innovative therapies: If eligible, patients may have access to CAR-T, bispecifics, or antibody-based regimens through trials or approved indications, depending on location and line of therapy. Discuss eligibility with your oncologist and local cancer centers.[8][4]
- Importance of molecular profiling: Biomarkers and risk stratification continue to influence treatment decisions, including selecting patients for specific combinations or immunotherapies. This may include assessment of disease biology and prior therapies.[4][1]
- Side effect management: With newer modalities, managing side effects (cytopenias, ocular toxicity with some antibody-drug conjugates, cytokine release syndrome, neurotoxicity) remains essential, and centers often have established protocols.[8][1]
Illustrative example
- A recent major milestone involved a BCMA-directed therapy demonstrating meaningful progression-free survival in relapsed/refractory myeloma in a pivotal trial, contributing to the evolving treatment landscape that blends traditional regimens with targeted immunotherapies. This reflects the ongoing shift toward deeper, more durable responses in myeloma care.[1]
Sources you can check for deeper, up-to-date details
- International Myeloma Foundation updates and trial summaries, including BCMA CAR-T and multi-target approaches.[1]
- Berenson Cancer Center news and analysis of emerging myeloma therapies and predictors of response.[2]
- NCI and EBMT pages summarizing advances in myeloma research and notable therapy approvals.[3][4]
- WebMD and Blood Cancers Today provide ongoing news coverage and patient-focused summaries.[9][10]
If you’d like, I can pull the most current specific headlines by date from these sources and summarize the top 3–5 items, or tailor the update to your location in the UK and any specific treatments you’re interested in.